Persistence with weekly and monthly bisphosphonates among postmenopausal women: Analysis of a US pharmacy claims administrative database

ClinicoEconomics and Outcomes Research

Volumn 5, Issue 1, 2013, Pages 589-595

  Fan, Tao ^a   Zhang, Qiaoyi ^a   Sen, Shuvayu S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adherence; Alendronate; Bisphosphonates; Ibandronate; Osteoporosis; Risedronate

Indexed keywords

ALENDRONIC ACID; IBANDRONIC ACID; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PATIENT ATTITUDE; PATIENT COMPLIANCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT WITHDRAWAL;

EID: 84887938996     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S39076     Document Type: Article

References (57)

1. Strewler GJ. Decimal point - osteoporosis therapy at the 10-year mark. N Engl J Med. 2004;350(12):1172-1174.
2. Orsini LS, Rousculp MD, Long SR, Wang S. Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures. Osteoporos Int. 2005;16(4):359-371.
3. US Department of Health and Human Services. Bone health and osteoporosis: a report of the surgeon general. 2003. Available from: http://www.surgeongeneral.gov/library/bonehealth. Accessed July 24, 2006.
4. Kuehn BM. Better osteoporosis management a priority: impact predicted to soar with aging population. JAMA. 2005;293(20):2453-2458.
5. Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2005;353(6):595-603.
6. Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354(21):2250-2261.
7. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;359(9322):2018-2026.
8. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077-2082.
9. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535-1541.
10. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11(1):83-91.
11. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999;282(14):1344-1352.
12. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis. 2006;65(5):654-661.
13. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
14. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med. 1997;102(2A):43-49.
15. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48(3):271-287.
16. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89(3):1117-1123.
17. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21(9):1453-1460.
18. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165(20):2414-2419.
19. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005;80(7):856-861.
20. Negri AL. Short-term compliance with alendronate 70 mg in patients with osteoporosis: the ECMO trial [abstract]. Bone. 2003;25(Suppl 5):S209.
21. Ettinger M, Gallagher R, Amonkar M, Smith J, MacCosbe P. Medication persistence is improved with less frequent dosing of bisphosphonates but remains inadequate. Arthritis Rheum. 2003;50:S513-S514.
22. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15(12):1003-1008.
23. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006;38(6):922-928.
24. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 2003;14(12):965-968.
25. Sebaldt RJ, Shane LG, Pham B, et al. Longer term effectiveness outcomes of noncompliance and nonpersistence with daily regimen of bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care [abstract]. Osteoporos Int. 2004;15 Suppl 1:S107.
26. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189-1199.
27. Weiss TW, Gold DT, Silverman SL, McHorney CA. An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study. Curr Med Res Opin. 2006;22(5):949-960.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc. 1958;53(282):457-481.
29. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074-1090.
30. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105-116.
31. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care. 1988;26(8):814-823.
32. Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther. 2002;24(11):1871-1886.
33. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-1310.
34. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150(9):1881-1884.
35. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261(22):3273-3277.
36. Kassirer JP. Incorporating patients' preferences into medical decisions. N Engl J Med. 1994;330(26):1895-1896.
37. Solomon DH, Brookhart MA, Gandhi TK, et al. Adherence with osteoporosis practice guidelines: a multilevel analysis of patient, physician, and practice setting characteristics. Am J Med. 2004;117(12):919-924.
38. Papaioannou A, Ioannidis G, Adachi JD, et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int. 2003;14(10):808-813.
39. Unson CG, Siccion E, Gaztambide J, Gaztambide S, Mahoney TP, Prestwood K. Nonadherence and osteoporosis treatment preferences of older women: a qualitative study. J Womens Health (Larchmt). 2003;12(10):1037-1045.
40. Coyle D, Wells G, Graham I, Lee KM, Peterson JE, Papadimitropoulos E. The impact of risk on preference values: implications for evaluations of postmenopausal osteoporosis therapy. Value Health. 2001;4(5):385-391.
41. Bowling A, Ebrahim S. Measuring patients' preferences for treatment and perceptions of risk. Qual Health Care. 2001;10 Suppl 1:i2-i8.
42. Jahng KH, Martin LR, Golin CE, DiMatteo MR. Preferences for medical collaboration: patient-physician congruence and patient outcomes. Patient Educ Couns. 2005;57(3):308-314.
43. Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin. 2005;21(12):1895-1903.
44. Christakis NA, Allison PD. Mortality after the hospitalization of a spouse. N Engl J Med. 2006;354(7):719-730.
45. Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367(9527):2010-2018.
46. Devogelaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone. 1996;18(2):141-150.
47. Karpf DB, Shapiro DR, Seeman E, et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA. 1997;277(14):1159-1164.
48. Cranney A, Wells G, Willan A, V et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002;23(4):508-516.
49. Epstein S, Cryer B, Ragi S, et al. Disintegration/dissolution profiles of copies of Fosamax (alendronate). Curr Med Res Opin. 2003;19(8):781-789.
50. Wehren LE, Hosking D, Hochberg MC. Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis. Curr Med Res Opin. 2004;20(4):525-531.
51. Bracco OL, Lazaretti-Castro M, Russo LA, et al. Clinical reasons for prescribing raloxifene or alendronate in Brazil [abstract]. J Bone Miner Res. 2003;18:S379.
52. Turbí C, Herrero-Beaumont G, Acebes JC, et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther. 2004;26(2):245-256.
53. Anderson R, Ross V. Questions of Communications: A Practical Introduction to Theory, 2nd ed. New York: St Martin's Press; 1998.
54. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346(9):653-661.
55. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821-831.
56. Johnell O, Kanis J, Gullberg G. Mortality, morbidity, and assessment of fracture risk in male osteoporosis. Calcif Tissue Int. 2001;69(4):182-184.
57. Borgström F, Johnell O, Jönsson B, Zethraeus N, Sen SS. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone. 2004;34(6):1064-1071.